TME Pharma buys time with €500K bond issue, pushes debt to June 2028
What's the deal? TME Pharma has secured a package of financial agreements to extend its runway into the second quarter of 2028. The deal includes a €500,000 bond issue subscribed by Hexagon Capital Fund, plus a 13-month extension on all existing debt, moving its maturity from May 28, 2027, to June 30, 2028.
What does it do? The biotech develops therapies for cancer and eye diseases, led by its NOX-A12 cancer candidate. CEO Diede van den Ouden took the helm in June 2025.
The structure: The refinancing is designed to avoid equity dilution, with the new bond repaid through cash amortisation payments. In return, Hexagon receives two million three-year share warrants at an exercise price of €0.15 — so the package is not entirely dilution-free. The new debt carries 10% interest, alongside a separate €250,000 CEO loan.
Why now? The move follows a March extension that had already pushed the company's runway past 12 months. It also comes as TME pursues a licensing deal for NOX-A12, saying in August it was in advanced talks with two potential partners and now describing those negotiations as concrete.
What's the endgame? The financing buys TME more time to land a partner that could fund further development. Its existing debt now totals about €2.4 million in nominal value after the extension.
What could go wrong? The package extends maturities rather than resolving the company's underlying funding needs. Its significance ultimately rests on whether the licensing talks produce cash and support.
The signal: For a small-cap biotech, refinancing without a fresh equity raise is a way to preserve shareholder value while chasing a catalyst. But it is a holding pattern — one that only pays off if a licensing deal closes before the new June 2028 deadline.
Read more: ca.marketscreener.com
Image credit: History at NIH
